Cardiogenic shock cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
Line 6: Line 6:


==Cost-Effectiveness==
==Cost-Effectiveness==
Attending to the fact that cardiogenic shock is a lethal condition, with a high [[mortality rate]], if not [[diagnosis|diagnosed]] early and [[therapy|treatment]] started in the shortest time-span possible, an aggressive [[diagnostic]] and [[therapeutic]] approach are of uttermost importance, therefore justifying the costs involved in the procedures.
Attending to the fact that cardiogenic shock is a lethal condition, with a high [[mortality rate]], if not [[diagnosis|diagnosed]] early and [[therapy|treatment]] started in the shortest time-span possible, an aggressive [[diagnostic]] and [[therapeutic]] approach are of uttermost importance, therefore justifying the costs involved in the procedures. An evidence of the effectiveness of timely and adequate diagnosis and treatment of cardiogenic shock is the important decrease in its mortality rate seen since mid 1970's.


==References==
==References==

Revision as of 15:51, 31 May 2014

Cardiogenic Shock Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiogenic shock from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiogenic shock cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiogenic shock cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiogenic shock cost-effectiveness of therapy

CDC on Cardiogenic shock cost-effectiveness of therapy

Cardiogenic shock cost-effectiveness of therapy in the news

Blogs on Cardiogenic shock cost-effectiveness of therapy

Directions to Hospitals Treating Cardiogenic shock

Risk calculators and risk factors for Cardiogenic shock cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Cost-Effectiveness

Attending to the fact that cardiogenic shock is a lethal condition, with a high mortality rate, if not diagnosed early and treatment started in the shortest time-span possible, an aggressive diagnostic and therapeutic approach are of uttermost importance, therefore justifying the costs involved in the procedures. An evidence of the effectiveness of timely and adequate diagnosis and treatment of cardiogenic shock is the important decrease in its mortality rate seen since mid 1970's.

References


Template:WikiDoc Sources